Peptides DB
Research-centric peptide and protocol reference hub
Study 10 of 13Humanin literatureReproductive biology · Observational · Preclinical2026

Humanin peptide ameliorates reproductive dysfunction and restores neuroendocrine mechanisms in SSRI-treated male rats.

Humanin may help mitigate reproductive dysfunction caused by SSRIs in male rats, but further research is needed to confirm these effects in humans.

Read at Reproductive biologyAdd to compare

Where it sits

this study against the rest of the humanin corpus
4
Preclinical
8
Observational · this one
0
Open-label
0
Randomised
1
Reviews

Summary and findings

This study measured the effects of humanin on reproductive dysfunction in male Sprague-Dawley rats treated with paroxetine (20 mg/kg/day). The research aimed to evaluate sexual behavior, sperm quality, serum hormones, and dopaminergic activity. Humanin (1 mg/kg/day) was administered via subcutaneous infusion alongside paroxetine, and significant reversals of adverse effects were reported.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.Preclinical2026

Abstract

The authors’ words, as Reproductive biology supplied them

Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine frequently induce male sexual dysfunction by disrupting neuroendocrine balance and central dopaminergic pathways. This study investigated whether humanin, a mitochondria-derived peptide, could mitigate paroxetine-induced reproductive and behavioral impairments in male Sprague-Dawley rats. In Phase 1, fifty rats were randomized into control, sham, paroxetine (20 mg/kg/day via oral gavage), humanin (1 mg/kg/day via subcutaneous infusion), and paroxetine + humanin groups (n = 10/group) to evaluate sexual behavior, sperm quality, serum hormones, and dopaminergic activity within the nucleus accumbens (NAc) and medial preoptic area (MPOA). In Phase 2, central neurochemical dynamics in a separate cohort of healthy rats (n = 8) were assessed using in vivo microdialysis coupled with HPLC-ECD to measure extracellular dopamine and its metabolites in the NAc. Paroxetine significantly impaired sexual motivation and performance, reduced sperm motility, concentration, and mitochondrial membrane potential, elevated prolactin, and suppressed testosterone, luteinizing hormone, and dopamine levels in both the NAc and MPOA (p < 0.05). Humanin co-administration significantly reversed these adverse effects, restoring ejaculatory frequency, copulatory efficiency, sperm parameters, and hormonal balance. Furthermore, humanin counteracted the paroxetine-induced dopaminergic suppression in the MPOA and NAc, while acute microdialysis revealed a supportive upward trend in dopamine turnover under basal conditions. These findings demonstrate that humanin exerts potent pro-fertility and neuroprotective effects against antidepressant-induced sexual dysfunction. By preserving mitochondrial integrity and modulating central dopaminergic and neuroendocrine circuits, humanin emerges as a promising therapeutic agent for preserving male reproductive health during SSRI treatment.

Background

The paper addresses the impact of SSRIs on reproductive dysfunction in male rats, a known concern in pharmacological treatments for depression. Prior studies have indicated that SSRIs can disrupt neuroendocrine functions, leading to reproductive issues. This study aims to explore whether Humanin peptide can counteract these effects, contributing to the understanding of neuroendocrine interactions in the context of antidepressant treatment.

Methods

The study design and specific methodologies were not detailed in the abstract. The population consisted of male rats treated with SSRIs, but the sample size, dosing regimen, and duration of treatment were not reported. Primary and secondary outcome measures were also not specified.

Results

Not reported in abstract.

Interpretation

Without specific results, it is challenging to compare these findings to existing literature or assess the clinical significance of the observed effects. The lack of detailed numeric data limits the ability to evaluate the magnitude of any potential benefits of Humanin. Additionally, the use of a rodent model introduces confounding factors that may not be applicable to human subjects.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.
  • Rodent model may not reflect human outcomes.
  • Specific numeric results not provided.
  • Sample size not reported.

Elsewhere in the Humanin corpus

CMitochondrial-derived peptide Humanin protects granulosa cells under oxidative conditions.Reproduction (Cambridge, England) · 2023 · n=30 · HN significantly decreased H2O2-induced granulosa cell apoptosis in KGN cells, p<0.01.AnimalCHumanin ameliorates diabetes-induced testicular damage in a streptozotocin-induced mouse model.Experimental physiology · 2026 · P < 0.05 for TAS and GSH levels in seminal vesicle fluid.AnimalCRepeated Humanin Treatment Attenuates Oxidative Stress, Inflammation, and Apoptosis in Diabetic Cardiac Tissue.Biology · 2026 · Not reported in abstract.AnimalCS14G-humanin (HNG) ameliorates diabetic nephropathy tubular injury by inhibiting Z-DNA/ZBP1-mediated necroptosis.European journal of pharmacology · 2026 · n=20 · UACR reduced by 49.5% (from 103.91 ± 7.68 to 52.50 ± 4.02 μg/mg, P < 0.001)AnimalCHumanin improved the rotenone-induced reactive oxygen species formation in PC12 cells by modulating the SIRT3/Nrf2/HO-1 signaling pathway.Toxicology and industrial health · 2026 · HN pretreatment significantly increased PC12 cell survival, p<0.001.In vitroBSerum mtDNA DAMP abundance, fragmentation and heteroplasmic variants associate with Acute Respiratory Failure outcome: A secondary analysis of study NCT00976833biorxiv-preprint · 2025 · Mean NUMT-depleted mtDNA insert size was lower in non-survivors.Human